Crystalvue Medical Corporation (6527) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Crystalvue Medical Corporation (6527:TWSE), powered by AI.

Current Price
$72.00
Sector
Healthcare
What is the Crystalvue Medical Corporation stock price forecast?

Crystalvue Medical Corporation is currently trading at $72.00. View real-time AI analysis on Alpha Lenz.

What is Crystalvue Medical Corporation insider trading activity?

View the latest insider trading data for Crystalvue Medical Corporation on Alpha Lenz.

What is Crystalvue Medical Corporation's P/E ratio?

View Crystalvue Medical Corporation's valuation metrics on Alpha Lenz.

Crystalvue Medical Corporation

TWSE · 6527
NT$72.00+0.50(+0.70%)
Ask about Crystalvue Medical Corporation's future dividend policy...
Alpha Chat Insight

Crystalvue Medical Corporation's ROE is 14.9%. Explore profitability and growth together.

Ask for details

Company Overview

Crystalvue Medical Corporation is a healthcare company specializing in the research, development, manufacturing, and global distribution of advanced ophthalmic diagnostic medical devices. Established in 2009 and headquartered in Taoyuan City, Taiwan, Crystalvue focuses on innovative solutions for eye care, producing devices such as fundus cameras, optical coherence tomography (OCT) systems, tonometers, lens edgers, and related medical instruments. The company's products play a crucial role in clinical diagnostics for eye health and vision care, serving professionals and healthcare institutions worldwide. Crystalvue also provides original design manufacturing (ODM) and original equipment manufacturing (OEM) services, supporting both branded and private-label medtech businesses. Certified under international standards like ISO 13485 and Taiwan GMP, Crystalvue emphasizes quality and regulatory compliance, with product certifications spanning the US FDA and European directives. The company has established a strong export footprint, with its self-developed devices sold in over 60 countries, contributing to both healthcare infrastructure and technological progress in ophthalmic medicine. Crystalvue Medical Corporation is recognized for its commitment to continuous innovation, stringent quality control, and supporting the advancement of minimally invasive diagnostic and therapeutic solutions in the global medical technology industry.

CEOWei Wang
SectorHealthcare
IndustryMedical Instruments & Supplies
Employees109

Company Statistics

FY 2025

Profile

N/AMarket Cap
NT$949.05MRevenue
0.00Shares Out
109Employees

Margins

34.97%Gross
20.79%EBITDA
19.07%Operating
18.86%Pre-Tax
15.49%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

6.06%Rev 3Yr
13.48%Rev 5Yr
13.18%Op Inc 3Yr
25.70%Op Inc 5Yr
8.51%Net Inc 3Yr
21.02%Net Inc 5Yr

Returns

11.85%ROA
14.94%ROE
14.47%ROIC

Financial Health

NT$132.02MCash & Cash Equivalents
NT$134.77MNet Debt
25.94%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Crystalvue Medical Corporation (ticker: 6527) is a company listed on TWSE in the Healthcare sector (Medical Instruments & Supplies). It has approximately 109 employees.

The current price is 72 with a P/E ratio of -x and P/B of -x.

ROE is 14.94% and operating margin is 19.07%. Annual revenue is $949M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Crystalvue Medical Corporation (6527) Stock Forecast 2026 $72.00 — Price, Financials & Analyst Targets | Alpha Lenz